<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aim: The aim of the study was to investigate, whether type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> independently influences adipokines and inflammatory markers in patients with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Methods: 36 patients with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> without type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and 39 patients with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, carefully matched for age, sex, and BMI, were investigated </plain></SENT>
<SENT sid="2" pm="."><plain>Primary outcome measures were circulating adipokines and inflammatory markers (adiponectin, leptin, visfatin, vaspin, resistin, TNF-α, IL-6, monocyte chemoattractant protein-1 (<z:chebi fb="17" ids="50099">MCP</z:chebi>-1), <z:chebi fb="1" ids="50211">retinol</z:chebi> binding protein 4 (RBP-4), growth differentiation factor-15 (GDF-15)) </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, we determined parameters of <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism </plain></SENT>
<SENT sid="4" pm="."><plain>Results: Patients with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> had significantly lower levels of plasma total cholesterol, <z:chebi fb="1" ids="47774">low-density lipoprotein cholesterol</z:chebi> and <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (p &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>They displayed higher GDF-15 concentrations (1,113 ± 135 vs. 656 ± 63 pg/ml, p = 0.005) and lower visfatin concentrations (3.7 ± 0.3 vs. 4.8 ± 0.2 ng/ml, p = 0.009) </plain></SENT>
<SENT sid="6" pm="."><plain>There were no differences in other adipokines and inflammatory markers between both groups </plain></SENT>
<SENT sid="7" pm="."><plain>Conclusions: In patients with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> leads to decreased visfatin and increased GDF-15 serum levels when compared to carefully matched non-diabetic subjects </plain></SENT>
<SENT sid="8" pm="."><plain>Whether the increase in GDF-15 is an indicator or a causal factor for the increased cardiovascular risk in diabetic subjects remains to be investigated in further studies </plain></SENT>
<SENT sid="9" pm="."><plain>Copyright © 2012 S </plain></SENT>
<SENT sid="10" pm="."><plain>Karger GmbH, Freiburg </plain></SENT>
</text></document>